Appatinib Combined With S-1 in the Treatment of Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the objective remission rate and disease control rate of apatinib mesylate
tablets combined with S-1 in the treatment of advanced small cell lung cancer patients with
failed or dangerous radiotherapy or chemotherapy
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital